Trevi Therapeutics Inc (TRVI)
NASDAQ:TRVI
Want to see TRVI full AI Analyst Report?
Earnings Data
Report Date
Aug 06, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.1Last Year’s EPS
-0.09Same Quarter Last Year
Strong Buy
Based on 8 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed solid execution progress: a strengthened balance sheet (pro forma cash ~ $334M) with runway into 2030, positive FDA alignment for IPF-related chronic cough, near-term trial initiations (Phase III IPF, Phase IIb RCC), an adaptive plan for non-IPF-ILD pending FDA agreement, expansion of IP filings and active scientific visibility (ATS, Investor Day). Principal risks discussed include competitor P2X3 readouts, possible trial upsizing via SSRE (and associated costs/timing), placebo variability in RCC, and regulatory dependence for the non-IPF-ILD program. On balance, the company presented multiple material positives and manageable risks tied to execution and external competitive/regulatory factors.Company Guidance
Strong Cash Position and Recent Financing
Ended Q1 2026 with ~$172M in cash, cash equivalents and marketable securities, plus $162M in net proceeds from an April 2026 underwritten common stock offering (total pro forma cash ~ $334M). Management states the financing extends runway into 2030 and removes financial overhang ahead of key clinical value inflection points.
Regulatory Alignment and Near-Term Trial Initiations
Positive FDA meeting for the IPF-related chronic cough program; finalized Phase III protocols and global site identification. Expect to initiate first of two pivotal Phase III IPF studies this quarter and the second in H2 2026. Intend to submit protocol/meeting request for a proposed adaptive Phase II/III non-IPF-ILD program and aim to initiate that trial in H2 2026 if aligned with FDA.
RCC Phase IIb Trial Design and SSRE
Plan to initiate a Phase IIb parallel-arm, dose-ranging RCC trial this quarter (3 doses + placebo). Trial includes a sample size reestimation (SSRE) at 50% completion, with SSRE readout expected in Q4 2026, using conditional power rules (80% target for staying on track; futility region around ~30–40%).
Intellectual Property Advancement
Core method-of-treatment patent for IPF-related chronic cough issued in Europe (previously issued in U.S.), providing protection through 2039. Additional U.S. patent applications filed that, if issued, could extend coverage through 2046; management is prosecuting label-enablement patents (e.g., dosing, food/hepatic implications) to broaden protection.
Operational Momentum and Talent Additions
Company has scaled up hiring, adding approximately 10 employees since the Phase IIb results, including clinical and pulmonology expertise. Executives report active investigator engagement, CRO partnerships, and site qualification efforts to support multiple concurrent programs.
Scientific & Commercial Visibility
Six submissions accepted at the upcoming ATS conference (presentations/posters). Investor & Analyst Day planned with additional data and commercial learnings to be shared. Upcoming oral/poster data include dyspnea (breathlessness) analyses and CORAL sub-analyses that may bolster the clinical and payer value proposition.
Clinical Signal and Placebo Benchmark
CORAL trial placebo response reported below 20%, a favorable benchmark for IPF chronic cough. Management expects Haduvio to perform better than P2X3 peers' expected placebo-adjusted change (~15–20%), positioning the drug as differentiated (central + peripheral mechanism).
TRVI Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
TRVI Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 05, 2026 | $14.66 | $14.26 | -2.73% |
Mar 17, 2026 | $11.19 | $10.69 | -4.47% |
Nov 13, 2025 | $11.46 | $11.37 | -0.79% |
Aug 07, 2025 | $7.30 | $7.42 | +1.64% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Trevi Therapeutics Inc (TRVI) report earnings?
Trevi Therapeutics Inc (TRVI) is schdueled to report earning on Aug 06, 2026, After Close (Confirmed).
What is Trevi Therapeutics Inc (TRVI) earnings time?
Trevi Therapeutics Inc (TRVI) earnings time is at Aug 06, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is TRVI EPS forecast?
TRVI EPS forecast for the fiscal quarter 2026 (Q2) is -0.1.